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Identification of Cysteine- Rich Angiogenic Inducer 61 as 
a Potential Antifibrotic and Proangiogenic Mediator in 
Scleroderma
Pei-Suen Tsou, Dinesh Khanna, and Amr H. Sawalha
Objective. We previously identified CYR61 as a histone deacetylase 5 (HDAC- 5)–repressed gene in systemic 
sclerosis (SSc; scleroderma) endothelial cells (ECs). When overexpressed, cysteine- rich angiogenic inducer 61 (CYR- 
61) promoted angiogenesis in SSc ECs. This study was undertaken to examine the role of CYR- 61 in fibrosis and 
determine the mechanisms involved in CYR- 61–mediated angiogenesis in SSc.
Methods. Dermal ECs and fibroblasts were isolated from biopsy specimens from healthy subjects and patients 
with SSc. CYR- 61 level was determined by quantitative polymerase chain reaction, Western blotting, and enzyme- 
linked immunosorbent assay. CYR- 61 was overexpressed using a CYR61 vector or knocked down using small inter-
fering RNA, and functional and mechanistic studies were then conducted in fibroblasts and ECs.
Results. Lower CYR 61 messenger RNA levels were observed in dermal fibroblasts and ECs from SSc patients 
than in those from healthy controls. In SSc fibroblasts, overexpression of CYR- 61 led to significant reduction in 
the expression of profibrotic genes, including COL1A1 (P = 0.002) and ACTA2 (P = 0.04), and an increase in the 
 expression of matrix- degrading genes, including MMP1 (P = 0.002) and MMP3 (P =0.004), and proangiogenic VEGF  
(P = 0.03). The antifibrotic effect of CYR- 61 was further demonstrated by delay in wound healing, inhibition of gel 
contraction, inactivation of the transforming growth factor β pathway, and early superoxide production associated 
with senescence in SSc fibroblasts. In SSc ECs, overexpression of CYR- 61 led to increased production of vascular 
endothelial cell growth factor. The proangiogenic effects of CYR- 61 were mediated by signaling through αvβ3 recep-
tors and downstream activation of AMP- activated protein kinase, AKT, and the endothelial cell nitric oxide synthase/
nitric oxide pathway system.
Conclusion. CYR- 61, which is epigenetically regulated by HDAC- 5, is a potent antifibrotic and proangiogenic 
mediator in SSc. Therapeutic intervention to promote CYR- 61 activity or increase CYR- 61 levels might be of benefit 
in SSc.
INTRODUCTION
Systemic sclerosis (SSc; scleroderma) is a connective 
tissue disease that is characterized by immune activation, 
vascular abnormalities, and progressive fibrosis in the skin 
and internal organs. It is a rare disease with a prevalence of 
150–300 cases per million in Europe and the US (1). This dis-
ease is associated with significant morbidity and can lead to 
life- threatening complications, including pulmonary arterial 
hypertension, interstitial lung disease, and scleroderma renal 
crisis. Although the etiology of SSc is still unclear, activation of 
immune cells and abnormalities of fibroblasts and endothelial 
cells (ECs) contribute to the pathogenesis of the disease (2). In 
addition, dysregulation of epigenetic mechanisms in SSc has 
been implicated in various cell types, and the use of epigenetic 
modifying drugs has been shown to be beneficial in cells as 
well as in animal models of SSc (2).
We recently showed that overexpression of the 
 antiangiogenic histone deacetylase 5 (HDAC- 5) in SSc ECs 
contributes to impaired angiogenesis by repressing proangio-
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genic factors (3). We took an unbiased approach to examine 
genome- wide changes in chromatin accessibility after HDAC- 5 
knockdown in ECs using an assay for transposase- accessible 
chromatin with sequencing. HDAC- 5 knockdown led to 
increased chromatin accessibility, and through bioinformatics 
analyses and functional assays we identified novel HDAC- 5 tar-
get genes associated with impaired angiogenesis in SSc ECs, 
including CYR61.
Cysteine- rich angiogenic inducer 61 (CYR- 61) is a mem-
ber of the CCN protein family (CYR- 61, connective tissue 
growth factor [CTGF], nephroblastoma- overexpressed gene, 
and Wnt- 1–inducible signaling pathway proteins 1–3), which 
plays important roles in development, inflammation, tissue 
repair, and a broad range of pathologic processes including 
fibrosis and cancer (4). CYR- 61 assumes its diverse functions 
by its ability to bind different combinations of co- receptors. 
For example, CYR- 61 promotes EC proliferation and sur-
vival through binding to αvβ3 (5,6), but enhances fibroblast 
adhesion and senescence through binding to α6β1 and hep-
aran sulfate proteoglycans (HSPGs) (7,8). Since this matri-
cellular protein supports angiogenesis (6,9) and possesses 
antifibrotic properties (8,10), we hypothesize that CYR- 61 
promotes angiogenesis and inhibits fibrosis in SSc ECs and 
fibroblasts, respectively. In this study, we characterized the 
expression and function of CYR- 61 in diffuse SSc dermal fibro-
blasts, and  further dissected the mechanisms involved in the 
 proangiogenic properties of CYR- 61 in this disease.
PATIENTS AND METHODS
Patients and controls. Two 4- mm punch biopsy spec-
imens from the distal forearm of healthy controls and patients 
with SSc were obtained for fibroblast and EC isolation. Plasma 
samples from the study participants were also collected to 
assess plasma CYR- 61 protein levels. All patients met the Amer-
ican College of Rheumatology/European League Against Rheu-
matism criteria for the classification of SSc (11). This study was 
approved by the Institutional Review Board of the University of 
Michigan and all study participants signed a written informed 
consent. The demographic and clinical characteristics of the 
study participants are summarized in Table 1.
Cell culture. Dermal fibroblasts and ECs were isolated and 
characterized as previously described (12–14). After digestion, 
ECs were purified using a CD31 MicroBead Kit (Miltenyi Biotec) 
and grown in EBM- 2 media with growth factors (Lonza). Fibro-
blasts were maintained in RPMI supplemented with 10% fetal 
bovine serum (FBS). Cells between passage 3 and 6 were used 
in all experiments.
CYR- 61 overexpression. Overexpression of CYR- 61 in 
ECs was induced as previously described (3). ECs were trans-
fected with 1.65 μg of CYR61 (control vector pCMV6- XL4; Ori-
Gene) and Lipofectamine 2000 (3.3 μl; Invitrogen) for 24 hours 
in T12.5 flasks. Five hours after transfection, culture media were 
changed to allow cells to grow in endothelial growth medium sup-
plemented with bovine brain extract (Lonza). To overexpress CYR- 
61 in dermal fibroblasts, 1 μg of CYR61 and 1 μl of Lipofectamine 
2000 were used to transfect the cells in a 12- well plate for a total 
of 48 hours.
CYR- 61 knockdown. CYR- 61 expression was knocked 
down using CYR61 small interfering RNA (siRNA) (On- Target 
Plus siRNA; Dharmacon), while a nontargeting siRNA (Dharma-
con) was used as a control. Fibroblasts isolated from healthy 
controls were transfected with 350 nM of siRNA using TransIT‐
TKO transfection reagent (Mirus Bio) for 48 hours before mes-
senger RNA (mRNA) was collected.
Western blotting. After obtaining cell lysates from cul-
tured cells, proteins were separated by sodium dodecyl sul-
fate–polyacrylamide gel electrophoresis and electroblotted onto 
nitrocellulose membranes. Antibodies used included phospho–
transforming growth factor β receptor type II (phospho- TGFβRII; 
Thermo Scientific), CYR- 61, TGFβRII, p21, and p16 (all from 
Abcam), phospho–retinoblastoma protein (phospho-pRB), pRB, 
TGFβ, phospho- Smad2, phospho- Smad3, Smad2/3, p53, 
phospho- p38, p38, phospho–endothelial cell nitric oxide syn-
thase (phospho- eNOS), eNOS, phospho- AKT, AKT, phospho–
AMP- activated protein kinase (phospho- AMPK), and AMPK (all 
from Cell Signaling Technology). β- actin was used as a loading 
Table 1. Characteristics of the SSc patients and healthy controls*
SSc patients 
(n = 62)
Age, mean ± SD years 55.8 ± 1.7
Sex, female/male 50/12
dcSSc 41
Disease duration, mean ± SD years 8.9 ± 1.4
Modified Rodnan skin thickness score, 
mean ± SD 
12.2 ± 1.3
Raynaud’s phenomenon 56
Early disease (<5 years) 37
Digital ulcers 12
Telangiectasias 27
Gastrointestinal disease 47
Interstitial lung disease 29
Pulmonary arterial hypertension 16
Renal involvement 3
* In the healthy control group (n = 40), there were 31 women and 
9 men, and the mean ± SD age was 49.5 ± 2.5 years. Except where 
indicated otherwise, values are the number of subjects. SSc = 
systemic sclerosis; dcSSc = diffuse cutaneous SSc. 
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control (Sigma- Aldrich). Band quantification was performed 
using ImageJ software (15).
Messenger RNA extraction and quantitative reverse 
transcriptase–polymerase chain reaction (PCR). Total 
RNA from ECs and fibroblasts was isolated using a Direct- zol 
RNA  MiniPrep kit (Zymo Research). A Verso complementary DNA 
(cDNA) synthesis kit was used to prepare cDNA (Thermo Sci-
entific). Primers for human CYR61, COL1A1, ACTA2, PPARG, 
MMP1, MMP3, TGFB, TGFBR2, VEGF, FGF2, CDK1A, and 
ACTB along with Power SYBR Green PCR Master Mix (Applied 
Biosystems), were used in quantitative PCR, which was run on 
a ViiA 7 Real- Time PCR System. Primers used were KiCqStart 
SYBR Green primers from Sigma-Aldrich or QuantiTect Primer 
Assays from Qiagen.
Enzyme- linked immunosorbent assay (ELISA). After 
transfection with CYR61 or control vectors, cell culture media 
were changed to RPMI (for fibroblasts) or EBM- 2 (for ECs) with 
0.1% FBS and cultured overnight. The levels of CYR- 61, matrix 
 metalloproteinase 1 (MMP- 1), MMP- 3, vascular endothelial 
growth factor (VEGF), and basic fibroblast growth factor in cell 
culture supernatants were measured using ELISA kits from R&D 
Systems. Absorbance at 450 nm in each well was read using a 
microplate reader.
β- galactosidase measurement. To examine the effect of 
CYR- 61 on cell senescence, we measured β- galactosidase using 
a Senescence β- Galactosidase Staining Kit from Cell Signaling 
Technology.
Gel contraction and cell migration assays. The gel con-
traction assay was conducted as previously described (16). Forty- 
eight hours after CYR- 61 overexpression or knockdown, dermal 
fibroblasts were suspended in culture media at 2 × 106 cells/ml. A 
Cell Contraction Assay kit (Cell Biolabs) was used for gel contrac-
tion. The area of the gel was analyzed using ImageJ software (15). 
To evaluate the effect of CYR- 61 on cell migration, we performed 
cell migration assays using SSc fibroblasts transfected with con-
trol or CYR61 vectors. Transfected cells were grown to confluence 
and a wound gap was created. Culture media were replaced with 
RPMI with 0.1% FBS, and pictures were taken using an EVOS 
XL Core Cell Imaging System (Life Technologies) at 0 hours and 
48 hours after wounding. The gap difference was quantified using 
ImageJ software (15).
Immunofluorescence staining. Cells grown in 8- well 
chambers were fixed in 4% formalin and blocked. They were 
then probed with anti–Ki- 67 antibodies (Abcam) or anti- human 
p21 antibodies (Abcam). Alexa Fluor antibodies (Invitrogen) 
were  subsequently used. The nuclei were stained using DAPI 
 (Invitrogen). Ki- 67–positive and p21- positive cells were counted 
using ImageJ software (15). To measure superoxide levels, 
 dihydroethidium (DHE; Invitrogen) was used. After fixation, DHE 
(10 μM) was added to CYR61- transfected or control- transfected 
fibroblasts for 15 minutes, and then stained with DAPI. Fluores-
cence was detected using an Olympus FV500 confocal micro-
scope and photographs were taken at 400×.
Nitrite/nitrate measurement. To examine whether 
increased nitric oxide (NO) was present after CYR- 61 overexpres-
sion, nitrite and nitrate levels in cell culture supernatant, both sta-
ble metabolites for NO, were measured using an OxiSelect In Vitro 
Nitric Oxide (Nitrite/Nitrate) Assay Kit from Cell Biolabs.
Matrigel tube formation assay. In our previous study, 
we showed that CYR- 61 overexpression in SSc ECs resulted in 
increased tube formation (3). To examine whether this effect is medi-
ated through αvβ3 and its downstream pathways, we pretreated 
CYR- 61–overexpressing SSc ECs with neutralizing antibodies to 
αvβ3 (10 μg/ml) or inhibitors for AMPK (compound c; 10 μM) or 
AKT (LY297002; 20 μM) pathways before performing Matrigel tube 
formation assays. Treated SSc ECs were  suspended in EBM- 2 
with 0.1% FBS and plated in 8- well Lab- Tek chambers coated with 
growth factor–reduced Matrigel (BD Biosciences). Cells were fixed 
and stained after 6 hours of incubation. Quantitation of the tubes 
formed by ECs was performed using the Angiogenesis Analyzer 
function in ImageJ software (15). Pictures of each well were taken 
using an EVOS XL Core Cell Imaging System (Life Technologies).
Statistical analysis. Results are expressed as the mean ± 
SD. To determine the differences between the groups, Student’s t- 
test, paired t- test, or one- way analysis of variance was performed 
using GraphPad Prism software, version 6. P values less than 
0.05 were considered significant.
RESULTS
CYR- 61 expression in SSc. Since CYR- 61 is secreted and 
detected in blood, we first measured CYR- 61 levels in plasma 
collected from healthy controls and SSc patients. We observed 
no differences in CYR- 61 levels between healthy controls and 
SSc patients, including after stratifying patients into the cate-
gories diffuse cutaneous SSc (dcSSc) or limited cutaneous SSc 
(lcSSc) (Figure 1A). In dermal fibroblasts, there was significant 
down- regulation of CYR61 mRNA levels in both dcSSc and 
lcSSc fibroblasts compared to normal fibroblasts (Figure  1B). 
Protein levels of CYR- 61 were measured in dcSSc fibroblasts 
and were found to be similar to those in control fibroblasts, as 
indicated by levels of secreted CYR- 61 in supernatants or CYR- 
61 protein levels in cell lysates  (Figures 1C and D).
Antifibrotic properties of CYR- 61 in SSc. To eval-
uate the effect of CYR- 61 in dermal fibroblasts, we first 
CYR- 61 IS ANTIFIBROTIC AND PROANGIOGENIC IN SSc |      1353
 overexpressed CYR- 61 in normal fibroblasts. Overexpres-
sion of CYR- 61 led to a significant decrease in fibrotic mark-
ers, including COL1A1 and ACTA2, suggesting that CYR- 61 
is indeed antifibrotic in these cells (Supplementary Table 1, 
available on the Arthritis & Rheumatology web site at http://
onlin elibr ary.wiley.com/doi/10.1002/art.40890/ abstract). 
We then overexpressed CYR- 61 in dcSSc dermal fibro-
blasts. Similar to what was observed in normal fibroblasts, 
increased CYR- 61 led to a significant reduction in COL1A1 
and ACTA2 expression (Table  2). This was accompanied 
by a significant increase in the expression of antifibrotic 
PPARG as well as matrix- degrading MMP1 and MMP3. In 
addition to its effects on fibrosis- related genes, CYR- 61 
overexpression led to a significant increase in  angiogenic 
factors, such as VEGF and FGF2, in dcSSc fibroblasts 
(Table 2).
At the protein level, overexpression of CYR- 61 in dcSSc 
fibroblasts resulted in the release of significant amounts of 
 CYR- 61, MMP- 1, MMP- 3, and VEGF into the culture media 
(Figure 1E), suggesting that CYR- 61 can act in both an auto-
crine and a  paracrine manner. To further confirm the role of 
CYR- 61 in dermal fibroblasts, we knocked down CYR- 61 in 
normal  fibroblasts and showed that down- regulation of CYR- 61 
led to a profibrotic phenotype, as indicated by elevated levels of 
COL1A1 and ACTA2 and decreased levels of MMP1 and MMP3 
 (Supplementary Table 2, available on the Arthritis & Rheumatology 
Figure 1. Antifibrotic role of cysteine- rich angiogenic inducer 61 (CYR- 61) in dermal fibroblasts from patients with diffuse cutaneous systemic 
sclerosis (dcSSc). A, Expression of CYR- 61 in plasma from healthy controls (normal), all SSc patients, patients with limited cutaneous SSc 
(lcSSc), and patients with dcSSc. There were no differences among the groups. B, Levels of CYR61 mRNA in healthy controls, all patients with 
SSc, patients with lcSSc, and patients with dcSSc. CYR61 mRNA expression was lower in both dcSSc and lcSSc dermal fibroblasts than in 
normal fibroblasts. C, CYR- 61 levels in control and dcSSc fibroblast culture media. There was no difference between the 2 groups. D, Western 
blot (WB) (left) and Western blot band quantification (right) showing similar CYR- 61 protein levels in normal and dcSSc dermal fibroblasts. 
E, Significant increases in CYR- 61, matrix metalloproteinase 1 (MMP- 1), MMP- 3, and vascular endothelial growth factor (VEGF) in the culture 
media after overexpression of CYR- 61 protein in dcSSc dermal fibroblasts. F, Illustration (left) and quantification (right) of wound area (in pixels) 
in SSc dermal fibroblasts after overexpression of CYR- 61 using a CYR61 vector. At 48 hours the wound area was significantly wider in cells 
transfected with CYR61 vector than in cells transfected with control vector. G, Photograph (left) and quantification (right) of the gel area after 
overexpression of CYR- 61 in dcSSc fibroblasts in a gel contraction assay. The gel area was increased in cells transfected with CYR61 vector. In 
A–D, symbols represent individual subjects; horizontal lines and error bars show the mean ± SD. In G, bars show the mean ± SD.
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web site at http://onlin elibr ary.wiley.com/doi/10.1002/art.40890/ 
abstract).
To examine the antifibrotic effect of CYR- 61 in SSc fibro-
blasts, we performed 2 functional assays: a scratch wound 
assay and a gel contraction assay. Overexpression of CYR- 61 
resulted in slower migration of dcSSc fibroblasts (Figure  1F) 
and reduced gel contraction (Figure  1G). In addition, CYR- 61 
knockdown in normal dermal fibroblasts resulted in increased 
gel contraction (Supplementary Figure 1, available on the Arthri-
tis & Rheumatology web site at http://onlin elibr ary.wiley.com/
doi/10.1002/art.40890/ abstract), providing further evidence of 
the antifibrotic properties of CYR- 61 in SSc.
CYR- 61 induces senescence in SSc fibroblasts. After 
confirming the antifibrotic functional role of CYR- 61 in dcSSc 
fibroblasts, we examined the possible mechanism involved. We 
hypothesized that CYR- 61–overexpressing SSc fibroblasts are 
converted from extracellular matrix (ECM)–producing myofi-
broblasts into ECM- degrading senescent cells, since CYR- 61 
has been shown to trigger senescence by increasing reactive 
oxygen species (ROS) and activating the p38 pathway through 
α6β1 integrin and HSPGs (8,10,17). We first examined whether 
CYR- 61 affects cell proliferation, using the proliferation marker 
Ki- 67. As shown in Figure  2A, dcSSc fibroblasts transfected 
with CYR61 showed a significant reduction in Ki- 67 staining, 
indicating decreased proliferation. We then measured super-
oxide production after CYR- 61 overexpression. We found that 
superoxide levels increased after 24 hours of CYR- 61 over-
expression, reaching a peak after 48 hours (Figure 2B). At 72 
hours after transfection there was no difference in superoxide 
levels between control- transfected and CYR- 61–transfected 
cells. These results suggest that superoxide production is an 
early event in the CYR- 61–triggered senescence pathway. 
We then measured p21 expression, which is a marker for cell 
senescence. Both p21 mRNA and protein levels were signif-
icantly elevated in CYR- 61–overexpressing dcSSc fibroblasts 
(Figures 2C–E).
To further dissect the mechanism of CYR- 61–mediated fibro-
blast senescence, we examined whether different senescence 
pathways were involved. Since we observed an increase in ROS 
production (Figure  2B), and ROS can activate stress- activated 
kinases such as MAPKs and downstream p38 MAPK (18), we 
first determined whether p38 MAPK was activated after CYR- 61 
overexpression in dcSSc dermal fibroblasts. Increased levels of 
phospho–p38 MAPK were indeed observed in CYR- 61–overex-
pressing cells (Figure 2E). Because p38 MAPK activation results 
in increased transcriptional activity of p53 as well as up- regulation 
of p21 and p16, we further examined their expression in CYR- 61–
overexpressing cells. Similar to phospho–p38 MAPK, increased 
accumulation of p53, p21, and p16 was also observed in fibro-
blasts transfected with the CYR61 vector compared to those 
transfected with control vector (Figure 2E). Since all triggers and 
signaling cascades involved in cell senescence converge on the 
hypophosphorylated form of pRB, we showed that overexpres-
sion of CYR- 61 in dcSSc dermal fibroblasts led to a decrease in 
pRB phosphorylation (Figure 2E). Cell senescence after CYR- 61 
overexpression was also confirmed by β- galactosidase staining 
(Supplementary Figure 2, available on the Arthritis & Rheuma-
tology web site at http://onlin elibr ary.wiley.com/doi/10.1002/
art.40890/ abstract). These results indicate that the p38 MAPK, 
p53, and p16/phospho- pRB pathways contribute to CYR- 61–
induced fibroblast senescence.
CYR- 61 affects the TGFβ pathway in SSc fibroblasts. 
Because TGFβ is the most prominent growth factor in driving 
fibrosis and collagen production in SSc, we next investigated the 
effects of CYR- 61 on TGFβ signaling in control- transfected and 
CYR61- transfected dcSSc dermal fibroblasts. We found that cells 
overexpressing CYR- 61 showed attenuated phosphorylation of 
TGFβRII and Smad2/3 and reduced levels of TGFβ. The expres-
sion levels of total TGFβRII and Smad2/3 did not change after 
CYR- 61 overexpression (Figure 2E).
Characterization of proangiogenic mechanisms 
of CYR- 61 in SSc ECs. We previously showed that CYR61 
was overexpressed after HDAC- 5 knockdown in ECs, and that 
it mediated the antiangiogenic effects of HDAC- 5 in dcSSc 
ECs (3). To further confirm its role in SSc angiogenesis, we 
 overexpressed CYR- 61 in dcSSc ECs and showed that this 
led to increased angiogenic ability of SSc ECs (3). In the pres-
ent study we further dissected the mechanisms involved in the 
proangiogenic properties of CYR- 61 in SSc. We first deter-
mined whether CYR61 expression was altered in dcSSc ECs 
compared to normal ECs and found that CYR61 expression 
was lower in dcSSc ECs (Figure  3A). We hypothesized that 
overexpression of CYR- 61 in SSc ECs leads to increased 
secretion of CYR- 61 and other proangiogenic factors. We 
Table 2. Expression levels of mRNA for selected target genes after 
CYR- 61 overexpression in dcSSc dermal fibroblasts*
Gene
Fold change versus control- 
transfected cells P
CYR61 213 ± 233 0.002
COL1A1 0.73 ± 0.12 0.002
ACTA2 0.75 ± 0.34 0.04
PPARG 1.34 ± 0.49 0.01
MMP1 3.70 ± 5.32 0.002
MMP3 2.40 ± 1.62 0.004
FGF2 1.42 ± 0.53 0.01
VEGF 1.45 ± 0.98 0.03
* Values are the mean ± SD fold change in expression in cells trans-
fected with cysteine- rich angiogenic inducer 61 (CYR- 61) versus 
control- transfected cells after transfection for 48 hours (n = 10 pa-
tients with diffuse cutaneous systemic sclerosis [dcSSc]). 
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focused on VEGF since it is reported to be a CYR- 61–regu-
lated gene (19). At the mRNA level, CYR- 61 overexpression 
resulted in significant up- regulation of VEGF while FGF2, 
another proangiogenic mediator, remained unchanged (Fig-
ure 3B). We also measured secreted CYR- 61 and VEGF in the 
culture media in control and CYR- 61–overexpressing dcSSc 
ECs, and showed that overexpression of CYR- 61 in dcSSc 
ECs increased both CYR- 61 and VEGF secretion (Figures 3C 
and D).
To determine whether the receptor for CYR- 61, αvβ3, is pres-
ent on ECs, we measured the mRNA levels in both normal and 
dcSSc ECs. There was a significant increase in ITGAV and ITGB3 
expression in dcSSc ECs compared to normal cells (Figures 3E 
and F). In contrast, ITGAV and ITGB3 levels did not change in 
CYR- 61–overexpressing ECs (Supplementary Figure 3).
Since we established that the receptor for CYR- 61, αvβ3, 
is present on SSc ECs, and that overexpression of CYR- 61 
leads to increased CYR- 61 and VEGF secretion, we then 
delineated the cellular events that were involved. CYR- 61 was 
previously shown to promote angiogenesis in ECs by activat-
ing the AMPK pathway and the AKT/eNOS/NO pathway, both 
via αvβ3 (20,21). Therefore, we first measured mRNA levels of 
NOS3 (encoding eNOS) and found that it was up- regulated 
in CYR- 61–overexpressing dcSSc ECs (Figure  3B). At the 
protein level the expression of eNOS was variable; however, 
when we measured phospho- eNOS, it was clear that CYR- 61 
overexpression led to eNOS activation (Figure 3G). To exam-
ine whether the eNOS–NO cascade is involved in CYR- 61–
mediated angiogenesis, metabolites of NO were measured in 
culture media after control and CYR- 61 overexpression. As 
expected, activation of eNOS led to a significant increase in 
NO metabolites in CYR- 61–overexpressing cells (Figure 3H), 
suggesting that this pathway is involved in CYR- 61–medi-
ated angiogenesis in SSc ECs. We then examined whether 
the AMPK and AKT pathways were activated. As shown in 
Figure  3G, enhanced phosphorylation of AMPK and AKT 
were observed in CYR- 61–overexpressing dcSSc ECs. Taken 
together, these results suggest that CYR- 61 overexpression 
in dcSSc ECs leads to increased excretion of CYR- 61, which, 
through binding to αvβ3, activates the AMPK/AKT/eNOS path-
ways to promote angiogenesis.
To further confirm the involvement of αvβ3 in CYR- 61–medi-
ated angiogenesis in SSc ECs, we performed Matrigel tube for-
mation assays using CYR- 61–overexpressing dcSSc ECs in 
Figure 2. CYR- 61–induced senescence in dcSSc dermal fibroblasts. A–D, Decreased cell proliferation after overexpression of CYR- 61 in 
dcSSc dermal fibroblasts, as shown by Ki- 67 staining (A), an increase in superoxide production that peaked at 48 hours (B), increased p21 
(CDKN1A) mRNA levels (C), and increased p21 protein levels (D). In the left panels of A and D and in B, scale bars = 10 μm. In the right panels of 
A and D and in C, bars show the mean ± SD. E, Western blot showing activation of senescence pathways and impairment of the transforming 
growth factor β (TGFβ) pathway in CYR- 61–transfected dermal fibroblasts from 4 patients with dcSSc. The senescence pathways that were 
activated by CYR- 61 in dcSSc dermal fibroblasts included p53, p38, p21, and p16, ultimately leading to hypophosphorylation of retinoblastoma 
protein (pRB). In addition, the antifibrotic effect of CYR- 61 was mediated by inactivation of the TGFβ pathway, as indicated by reduced levels of 
phosphorylated TGFβ type II receptor and Smad2/3. See Figure 1 for other definitions.
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the presence or absence of blocking antibodies for αvβ3. The 
 proangiogenic property of CYR- 61 was blocked by the pres-
ence of the αvβ3 antibodies compared to the IgG isotype con-
trol (Figure 4A). In addition, inhibitors of AMPK (compound c) or 
AKT (LY294002) pathways blocked the proangiogenic activities of 
CYR- 61 (Figure 4B).
DISCUSSION
In this study, we examined the effect of CYR- 61 on both SSc 
fibroblasts and ECs. As illustrated in Figure 4C, overexpressing 
CYR- 61 in SSc fibroblasts attenuates fibrogenesis by inducing 
cellular senescence and impairing the TGFβ pathway. We showed 
that overexpressing CYR- 61 converted SSc fibroblasts from 
ECM- producing myofibroblasts into ECM- degrading senescent 
cells. This finding is supported by a reduction in fibrotic markers 
and an increase in matrix- degrading MMPs after overexpression 
of CYR- 61 in SSc fibroblasts. In addition, the myofibroblast phe-
notype was inhibited, as shown by functional assays. We also 
demonstrated that markers for cell proliferation were reduced, 
key mediators for cell senescence were elevated, and the activa-
tion of TGFβRII and downstream Smad pathways were inhibited. 
We believe this study provides sufficient evidence to support the 
notion that CYR- 61 is indeed antifibrotic in SSc fibroblasts.
CYR- 61 has been studied extensively in the skin, since it is 
a negative regulator of collagen homeostasis in fibroblasts, and is 
substantially elevated in aged and senescent human skin (22,23). 
CYR- 61 has been shown to trigger senescence by increas-
ing ROS and activating the p38 pathway through α6β1 integrin 
and HSPGs (8,10,17). In addition, it down- regulates TGFβRII 
and thereby impairs TGFβ responsiveness in fibroblasts (17,24). 
Although CYR- 61 blockade leads to improvement of fibrosis in 
lung and kidney fibrosis models (25,26), CYR- 61 has been shown 
to possess antifibrotic properties in animal models of cutaneous 
wound healing as well as liver fibrosis (8,10,17). We were able 
to recapitulate the involvement of the p38 MAPK pathway in cell 
senescence in CYR- 61–overexpressing SSc fibroblasts. However, 
instead of down- regulation of TGFβRII, we showed decreased 
 levels of TGFβ, possibly leading to inactivation of TGFβRII and its 
downstream Smad2/3 pathway in these cells.
Figure 3. CYR- 61 promotes angiogenesis in endothelial cells (ECs) from patients with dcSSc through αvβ3 integrin, endothelial cell nitric oxide 
synthase (eNOS), AMP- activated protein kinase (AMPK), and AKT. A, Significantly lower CYR61 mRNA levels in dcSSc ECs than in normal 
ECs. B, Significant increases in CYR61, VEGF, and NOS3 after overexpression of CYR- 61 in dcSSc ECs. C and D, Significant elevation of 
CYR- 61 (C) and VEGF (D) levels in culture media from CYR- 61–overexpressing dcSSc ECs. E and F, Elevated ITGAV (E) and ITGB3 (F) mRNA 
expression levels in dcSSc ECs compared to normal ECs. G, Western blot showing significant elevation of phosphorylated eNOS, AKT, and 
AMPK in CYR61-transfected dcSSc ECs. H, Increased levels of nitrates and nitrites (metabolites of nitric oxide) in culture media collected from 
CYR61-transfected dcSSc ECs. In A, B, E, F, and H, bars show the mean ± SD. See Figure 1 for other definitions.
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Interestingly, another member of the CCN family, CCN2/
CTGF, is also involved in fibrosis. Although CYR- 61 and CTGF 
share similar structures, receptors, and downstream signaling 
pathways, the subtle differences in their sequences alter the 
surface area and charge, thereby affecting their interactions 
with binding partners making them functionally unique (27). It 
is suggested that in wound healing, CYR- 61 and CTGF act as 
yin and yang; CTGF promotes myofibroblast proliferation and 
matrix deposition to provide tissue integrity and promote wound 
repair when wounding occurs, while CYR- 61 promotes wound 
resolution by inducing myofibroblast senescence and matrix 
degradation (8). CTGF, which promotes fibrosis, is elevated in 
SSc patients and plays key roles in myofibroblast transforma-
tion through interaction with the TGFβ pathway (28–30). The 
 imbalance between CTGF and CYR- 61 could play a major role 
in promoting fibrosis in SSc.
It has been suggested that CYR- 61 activates VEGF pro-
duction in fibroblasts through the α6β1/HSPG/ERK axis (31). 
We indeed found that CYR- 61–overexpressing SSc fibroblasts 
released elevated levels of VEGF (Figure  1E), prompting us to 
speculate that CYR- 61 can promote EC angiogenesis through 
fibroblasts (Figure 4C). This is possible, since cross- talk between 
ECs and fibroblasts in SSc has been documented (32). Although 
VEGF has a limited effect on SSc ECs (the so- called VEGF par-
Figure 4. A and B, Inhibition of the proangiogenic property of CYR- 61 by blockade of αvβ3 (A) or by inhibition of AMP- activated protein 
kinase (AMPK) or AKT (B). Photomicrographs (top panels) and quantification (bottom panels) of Matrigel tube formation assays using CYR- 
61–overexpressing dcSSc endothelial cells (ECs) are shown. The proangiogenic activity of CYR- 61 in promoting tube formation in dcSSc ECs 
was inhibited by αvβ3 blocking antibodies (ab). Pretreating the dcSSc ECs with inhibitors for AMPK (compound c [com C]) or AKT (LY294002) 
reduced tube formation significantly after CYR- 61 overexpression. Angiogenesis was shown by counting the number of nodes or the number of 
tubes, using ImageJ software. In top panels, original magnification × 4; in bottom panels, bars show the mean ± SD. C, CYR- 61 overexpression 
in dcSSc fibroblasts. CYR- 61 overexpression results in increased release of CYR- 61 that binds to α6β1 integrin/heparan sulfate proteoglycan 
(HSPG). CYR- 61 exerts antifibrotic properties by two mechanisms: 1) inducing senescence by reactive oxygen species (ROS) production, 
thereby activating p38/p16 or p38/p53/p21 pathways, and 2) attenuating the transforming growth factor β (TGFβ) pathway by inactivating the 
TGFβ/TGFβ receptor type II (TGFβRII) pathway. CYR- 61 can also increase VEGF release from fibroblasts, which may increase the angiogenic 
potential of ECs. Studies have suggested that CYR- 61 promotes VEGF production through activating the α6β1 integrin/HSPG–ERK pathway. 
D, CYR- 61 overexpression in dcSSc ECs. CYR- 61 overexpression results in increased CYR- 61 excretion, leading to improved angiogenesis 
by binding αvβ3 receptors and signaling through the AMPK/AKT/nitric oxide (NO) pathways. CYR- 61 can also increase the expression and 
excretion of proangiogenic VEGF, possibly through the AKT and AMPK pathways. The proangiogenic effect of VEGF is known to be mediated 
through the AKT and its downstream NO signaling pathway. eNOS = endothelial cell nitric oxide synthase (see Figure 1 for other definitions).
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adox), we showed previously that these cells do respond to 
higher levels of VEGF (33), which strengthens the argument that 
 overexpressing CYR- 61 in fibroblasts might increase the angio-
genic potential of SSc ECs.
In addition to the effect of CYR- 61 on fibroblasts, its effect 
on SSc ECs was also examined in this study (Figure 4D). CYR- 
61 overexpression in SSc ECs led to increased excretion of 
CYR- 61, which through binding to αvβ3, activated the AMPK/
AKT pathways to promote angiogenesis. CYR- 61 also acti-
vated expression of VEGF to further increase its proangiogenic 
potential. Both CYR- 61 and proangiogenic factors can act in 
an autocrine or a paracrine manner. The involvement of αvβ3 
and the AKT and AMPK pathways in CYR- 61–mediated angio-
genesis was supported by the findings of our experiments with 
blocking antibodies and inhibitors. Our results are consistent 
with those of previous studies suggesting the involvement of 
the AMPK pathway and the AKT/eNOS/NO pathway in CYR- 
61–mediated angiogenesis in ECs (20,21). The ability of CYR- 
61 to regulate VEGF was also documented (19). In addition, its 
angiogenic activity was observed in in vivo rat cornea models 
and ischemic rabbit hind limb models (20,21,34–38). Since 
CYR- 61 is also critical for EC survival (6,39) and increased 
apoptosis has been reported in SSc ECs (40), lower levels 
of CYR- 61 in SSc ECs could contribute to both the impaired 
angiogenesis and the increased apoptosis seen in these cells.
Inconsistent results have been reported for CYR- 61 serum 
levels in SSc (41,42). Similar to what we observed, Saigusa 
et  al (41) showed that serum CYR- 61 levels were compara-
ble among healthy controls, patients with dcSSc, and patients 
with lcSSc (41). They also showed that CYR- 61 was down- 
regulated in dermal small blood vessels of SSc patients com-
pared to controls, which is consistent with what we observed 
in this study (41).
We previously showed that CYR- 61 promotes EC tube for-
mation in dcSSc ECs (3). In this study, we compiled evidence to 
indicate that CYR- 61 is indeed proangiogenic and antifibrotic in 
SSc ECs and fibroblasts, respectively. Therefore, our data sug-
gest that up- regulating CYR- 61 in SSc might be of therapeutic 
potential in this disease. CYR- 61 attenuated two key patho-
logic mechanisms in SSc: impaired angiogenesis and increased 
fibrosis. CYR- 61 also modulates immune responses through 
macrophages (43,44), and the possibility that CYR- 61 inhibits 
macrophage- driven fibrosis by affecting macrophage polari-
zation and monocyte/macrophage migration warrants further 
investigation.
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